

Serial No. 10/749,593

Atty. Docket No. Mo 5346D2/LeA 32 314D2

REMARKS

Applicants respectfully request reconsideration and reexamination of the present application in light of the amendments and the remarks below.

Claims 3-7, 12 and 13 are pending in this application. Claims 4-6, 12, and 13 have been amended. These claim amendments are made to clarify the subject matter therein. Therefore, these amendments are submitted in order to place the claims in condition for allowance, and do not disclaim any subject matter to which the Applicants are entitled.

Specification

The Examiner stated that the disclosure is objected to because the term "aluminium chloride" recited on page 3, line 23 has an improper spelling.

The specification has been amended to correct the spelling of "aluminium chloride."

Rejection Under 35 U.S.C. § 112, first paragraph

The Examiner rejected claim 13 under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for a catalyst, such as a Lewis acid (e.g. iron chloride or aluminum chloride) does not reasonably provide enablement for all catalysts known in the art (Paper No. 20050902, pages 3-5).

To expedite prosecution, claim 13 has been amended to recite "Fridel-Crafts" catalysts. Support for the amendment may be found, for example, on page 3, line 22 of the specification.

It is thus submitted that the claim meet the requirements of 35 USC § 112, first paragraph, and reconsideration and withdrawal of the present rejection is respectfully requested.

Claim Objections

The Examiner objected to claims 4-6 and 12 because of the following informalities (Paper No. 20050902, page 3):

In claims 4 and 5, there are no periods in the ends of the claims. The claims have been amended accordingly.

In claims 4 and 6, there is an absence of the hyphen in the chemical term "2,4-dichloro-5fluoro-3-N-hydroxyiminomethyl-benzoic acid." The claims have been amended accordingly.

In claim 12, the chemical term "2,4-dichloro-5-fluoro-1,3-dimethylbenzened" is recited. The spelling of the chemical name has been corrected.

It is submitted that Applicants have overcome the claim objections, and thus, claims 4-6 and 12 are allowable.

Serial No. 10/749,593

Atty. Docket No. Mo 5346D2/LcA 32 314D2

Allowable Claims

The Examiner stated that claims 3 and 7 are allowable (Paper No. 20050902, page 2).

CONCLUSION


For the foregoing reasons, Applicants submit that the claims are in condition for allowance and Applicants respectfully request reexamination of the present application, reconsideration and withdrawal of the present rejections and objections, and entry of the amendments. Should there be any further matter requiring consideration, Examiner Oh is invited to contact the undersigned counsel.

If there are any further fees due in connection with the filing of the present reply, please charge the fees to undersigned's Deposit Account No. 13-3372. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,

Date: January 12, 2006

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175
Telephone: (203) 812-6450
Facsimile: (203) 812-6459


Susan M. Pellegrino
Attorney for Applicants
Reg. No. 48,972